Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Chromatin (Chicago, IL) a commercial-stage bioenergy market company focused on crop improvement and biomass feedstocks for the renewable energy sector closed a $10.4M Series D financing. Participants include BP Ventures, Unilever Technology Ventures, Quantitative Investment Holdings, Malaysian Life Sciences Capital Fund and Illinois Ventures.

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Coskata (Warrenville, IL) a development-stage bacterial fermentation biofuels company closed a $23.7M Series D financing. Participants include Total, Blackstone Group, Advanced Technology Ventures, Globespan Capital Partners, General Motors, GreatPoint Ventures and Khosla Ventures.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $30M Series A financing, bringing the total round to $113M. Participants include Vivo Ventures.

  

to top of page...